51. Fibrinogen Level among Sudanese Patients with Chronic Myeloid Leukemia
- Author
-
Tagreed Saif Aldeen Mostafa, Nihad Elsadig Babiker, and Maye M. Merghani
- Subjects
medicine.medical_specialty ,medicine.drug_class ,business.industry ,Anticoagulant ,Energy Engineering and Power Technology ,Myeloid leukemia ,Fibrinogen ,Malignancy ,medicine.disease ,Philadelphia chromosome ,Fibrinogen levels ,Fuel Technology ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Family history ,Risk factor ,business ,medicine.drug - Abstract
Background: Chronic myeloid leukemia (CML) is a malignancy of white blood cells, distinguished by the Philadelphia chromosome's presence. The biological profile of sufferers with CML at diagnosis is nevertheless missing in Africa, especially in Sudan. Therefore, the study pursued to measure the fibrinogen level among Sudanese patients diagnosed with CML attending the Radiation and Isotopes Centre of Khartoum. Methods: This descriptive perspective and the analytical casecontrol study were performed at the Radiation and Isotopes Centre of Khartoum from August to September 2021. In this study, fifty patients with CML were utilized as a case, and 50 healthy people were used as a control group. The blood samples from groups were collected in sodium citrate anticoagulant containers. Fibrinogen levels in the blood were determined by the Clauss technique using a coagulometer device. Results: There was a significant increase in fibrinogen levels between case and control groups. Further, age, gender, family history, and presence of chronic disease were non-significantly variations in CML patients. Moreover, smoking was considered a risk factor in CML. Conclusions: Fibrinogen level was significantly elevated in CML patients; additionally, there were significant differences associated with smoking, and there were non-significant differences related to age, gender, family history, presence of chronic disorder, and treatment.
- Published
- 2021
- Full Text
- View/download PDF